Secondary Metabolites of Oplopanax elatus: Possibilities for Standardization of a Multiphytoadaptogen for Preventive Oncology

An herbal formulation of a multiphytoadaptogen (MPA) developed at the N. N. Blokhin Cancer Center and containing phytocomponents from Oplopanax elatus Nakai has been studied in preclinical and clinical trials for preventive oncology. Secondary metabolites were identified in the extract of rhizomes and roots of O. elatus and in the MPA pharmaceutical composition using high performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Compounds identical to ginsenosides Rd and Re (tetracyclic triterpene saponins from Panax ginseng ) and araloside C and stipuleanoside R2 (pentacyclic triterpene saponins, oleanolic acid derivatives, from Aralia mandshurica ) were identified in the MPA and in the extract of rhizomes and roots of O. elatus . The spectra of biological activity of ginsenosides Rd and Re, araloside C, and stipuleanoside R2 were analyzed in silico using the PASS computer program. According to published data and in silico analysis, the activities of ginsenosides Rd and Re, araloside C, and stipuleanoside R2 correspond to properties previously confirmed in the MPA studies for preventive oncology.